About Us

In 2001, the late President George H.W. Bush, the forty-first President of the United States, asked Robert A. Ingram, then the CEO of GlaxoWellcome, to convene and chair the CEO Roundtable on Cancer, a national forum bringing together key cancer leaders from government, business, academia and nonprofit sectors, all of whom shared a common vision: eliminating cancer.

Leadership

​Board of Directors of the CEO Roundtable on Cancer
David M. Reese, MD
Chair, Board of Directors, CEO Roundtable On Cancer, Board Member, Project Data Sphere, Executive Vice President, Chief Technology Officer, Amgen
Christopher A. Viehbacher
Past Chairman, CEO Roundtable on Cancer, Board Member, Project Data Sphere, President and CEO, Biogen
James Goodnight, PhD
​Board Member, CEO Roundtable on Cancer, Board Member, Project Data Sphere, Co-Founder & Chief Executive Officer, SAS
John Crumpler
Board Member, CEO Roundtable on Cancer, Board Member, Project Data Sphere, General Partner, Hatteras Venture Partners
Norman “Ned” Sharpless, MD
​Board Member, CEO Roundtable on Cancer, Co-CEO, Jupiter BioVentures, Professor of Cancer Policy and Innovation, University of North Carolina School of Medicine, Former Director of US National Cancer Institute
Peter Guenter
​Board Member, CEO Roundtable on Cancer Executive Board Member, Merck CEO, Healthcare
Major General Elder Granger, MD
Board Member, CEO Roundtable on Cancer, Going for Gold Ambassador, President & CEO, THE 5Ps, LLC
Peter WT Pisters, MD, MHCM
​Board Member, CEO Roundtable on Cancer, President, University of Texas MD Anderson Cancer Cente
Scott White
Board Member, CEO Roundtable on Cancer, Company Group Chairman, North America Pharmaceuticals, Johnson & Johnson
Emeritus Directors of the CEO Roundtable on Cancer
Robert A. Ingram – In Memoriam
​Founding Chairman, CEO Roundtable on Cancer
Robert A. Bradway
Director Emeritus, CEO Roundtable on Cancer, Chairman and CEO, Amgen
Martin J. Murphy, DMedSc, PhD, FASCO
Director Emeritus, CEO Roundtable On Cancer
​William C. Weldon
​Chairman Emeritus, CEO Roundtable on Cancer, Former Chairman of the Board and Chief Executive Officer, Johnson & Johnson
Life Sciences Council
Emily Morris-McCarthy
​Member, Life Sciences Council, General Manager, Head U.S. Oncology, Sanofi
Brian Alexander, MD
Member, Life Sciences Council, ​SVP, Roche/Genentech Pharma R&D
​Jean-Charles Soria, MD, PhD
Co-Chair, Life Sciences Council, Head of Oncology Development at Amgen 
​Stuart “Stu” Bailey, DPhil
​Member, Life Sciences Council, Senior Vice President, EMD Serono Inc.
Peter Sandor, MD, MBA
Member, Life Sciences Council, Senior Vice President, Primary Focus Immuno-oncology, Astellas
Tara Frenkl, MD, MPH
​Member, Life Sciences Council, Head of Oncology Development, Bayer
Craig L. Tendler, MD
 Co-Chair, Life Sciences Council , Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Janssen Research & Development, LLC
Eliav Barr, MD
Member, Life Sciences Council, Head, Global Clinical Development, and Chief Medical Officer, Merck

Health and Well-Being Council

Otis W. Brawley, MD, MACP
​Member, Health & Well-Being Council, Bloomberg Distinguished Professor, Johns Hopkins University
​Aubrey Van Kirk Villalobos, DrPH, MEd
Member, Health & Well-Being Council, Health Scientist, Implementation Science Team, Division of Cancer Control and Population Sciences, National Cancer Institute
David Roomes, FRCP, FFOM, FACOEM
Member, Health and Well-being Council, Global Head, Occupational Health, Bristol Myers Squibb
​Ron Z. Goetzel, PhD
ember, Health & Well-Being Council, Senior Scientist And Director, Institute for Health and Productivity Studies, Johns Hopkins Bloomberg School of Public Health
Marcelo C. Targino, MD, MPH
Chair, Health & Well-Being Council, Chief Health Officer and Corporate Medical Director, Johnson & Johnson
Brian Kehan
​Member, Health & Well-Being Council, Director of Benefits and Well-being, Merck & Co., Inc.
Jennifer Mills, PhD, MSW, MPH
​ Member, Health & Well-being Council, Vice President, Medical Affairs, Foundation Medicine, Inc.

Going for Gold Ambassadors

​Major General Elder Granger, MD
Board Member, CEO Roundtable on Cancer, Going for Gold Ambassador, President & CEO, THE 5Ps, LLC
Otis W. Brawley, MD, MACP
​ Member, Health & Well-Being Council, Bloomberg Distinguished Professor, Johns Hopkins University
Fields Jackson, Jr
 Going for Gold Ambassador, CEO, Racing Toward Diversity Magazine
Marelli Colon Emeric, MD
​Going for Gold Ambassador
Joya Delgado-Harris, MPH
​ Going for Gold Ambassador, Gold Standard Executive Director, CEO Roundtable on Cancer
Cynthia Warrick, PhD
​ Going for Gold Ambassador, President Emerita, Stillman College, CEO, Society for Diversity in the Biomedical Sciences
Roberto A. Gonzalez
​ Going for Gold Ambassador, Founder, RA Gonzalez & Associates, Co-Founder, Cornerstone & Associates LLC
Robert J. Brown
​ Going for Gold Ambassador, CEO and Founder, B&C International 

CEO Roundtable on Cancer, Senior Leadership

Sean Khozin, MD, MPH
​CEO, CEO Roundtable on Cancer
Jon McDunn, PhD
​ President, Project Data Sphere

​​Ron Z. Goetzel, PhD

Ron Goetzel wears two hats. He is Senior Scientist and Director of the Institute for Health and Productivity Studies (IHPS) at the Johns Hopkins Bloomberg School of Public Health and Vice President of Consulting and Applied Research for IBM Watson Health. The mission of the IHPS is to bridge the gap between academia, the business community, and the healthcare policy world – bringing academic resources into policy debates and day-to-day business decisions, and bringing health and productivity management issues into academia. Before moving to Johns Hopkins University, Dr. Goetzel was on the faculty at Emory and Cornell Universities. Dr. Goetzel is responsible for leading innovative projects for healthcare purchaser, managed care, government, and pharmaceutical clients interested in conducting cutting-edge research focused on the relationship between health and well-being, medical costs, and work-related productivity. He is an internationally recognized and widely published expert in health and productivity management (HPM), return-on-investment (ROI), program evaluation, and outcomes research. Dr. Goetzel has published well over 200 peer-reviewed articles and book chapters and frequently presents at international business and scientific forums.

David Roomes, FRCP, FFOM, FACOEM

David is responsible for leading the Global Occupational Health function at Bristol Myers Squibb. His previous roles were with Rolls-Royce (aerospace and defense) Rio Tinto (mining) and GlaxoSmithKline (pharmaceuticals). David is a practicing physician and is a Fellow of the Royal College of Physicians, the Faculty of Occupational Medicine and the American College of Occupational and Environmental Medicine. His special interests include health equity; the intersection between climate and health; workplace mental health and wellbeing and workforce wellbeing as an enabler to enhance engagement, productivity, and performance.

Aubrey Van Kirk Villalobos, DrPH, MEd

Aubrey Van Kirk Villalobos, DrPH, MEd, is a Health Scientist with the Implementation Science (IS) Team in the Office of the Director in the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI). In this role she leads efforts to advance the involvement of practitioners in IS to enhance the integration of evidence-based guidelines, programs, and policies for cancer control in public health and clinical practice. Dr. Villalobos cultivates research-practice partnerships through participation in the Comprehensive Cancer Control National Partnership, Cancer Prevention and Control Research Network, and the Consortium for Cancer Implementation Science, and serves as an advisor on the Evidence Based Cancer Control Programs website and the Healthy People 2030 cancer workgroup. Prior to joining the NCI, Dr. Villalobos served as director of cancer control and health equity at the George Washington University (GW) Cancer Center where she supported strategic planning for the center’s community outreach and engagement activities and directed a multi-million-dollar portfolio of sponsored projects providing technical assistance and training to public health and health care professionals. Previously, she served as the cancer education outreach coordinator in the international outreach program at St. Jude Children’s Research Hospital. Dr. Villalobos’s scientific and programmatic interests include social and structural influences on health behaviors and inequities, particularly related to primary cancer and chronic disease prevention and early detection. Her mixed methods dissertation research focused on social norms and breastfeeding among African American women and was supported by fellowships from the Sumner M. Redstone Global Center for Prevention and Wellness and the Jacobs Institute of Women’s Health Clara Schiffer Project. She has expertise in social/behavioral science; community engagement and partnership-building; policy, systems, and environmental change for health promotion; and clinician, professional, patient and community education. Dr. Villalobos received a Doctor of Public Health in health behavior from the Milken Institute School of Public Health at the George Washington University in Washington, D.C., where she also earned a Master of Public Health in health promotion. She holds a Master of Education from Christian Brothers University in Memphis, TN and a Bachelor of Science in biological chemistry from Bates College in Lewiston, ME.

​Otis W. Brawley, MD, MACP

​Dr. Otis Brawley is a globally recognized expert in cancer prevention and control. He has worked to reduce over screening of medical conditions, which has revolutionized patient treatment by increasing quality of life and reducing health disparities. Dr. Brawley’s research focuses on developing cancer screening strategies and ensuring their effectiveness. He has championed efforts to decrease smoking and implement other lifestyle risk reduction programs, as well as to provide critical support to cancer patients and concentrate cancer control efforts in areas where they could be most effective. Dr. Brawley currently leads a broad interdisciplinary research effort on cancer health disparities at the Bloomberg School of Public Health and the Johns Hopkins Kimmel Cancer Center, striving to close racial, economic, and social disparities in the prevention, detection, and treatment of cancer in the United States and worldwide. He also directs community outreach programs for underserved populations throughout Maryland. He joined Johns Hopkins University as a Bloomberg Distinguished Professor in 2019 from the American Cancer Society and Emory University. He also is a former member of the FDA Oncologic Drug Advisory Committee (ODAC). Dr. Brawley is a current member of the National Cancer Institute’s (NCI) Board of Scientific Counselors. Formerly, Dr. Brawley was a professor in the Department of Hematology and Oncology at the Emory University School of Medicine. He was also previously a senior investigator at the National Institute of Health (NIH) and NCI. In 2013, he was the recipient of a Special Recognition Award from the American Society of Clinical Oncology. Dr. Brawley received an M.D. from the University of Chicago, Pritzker School of Medicine. He completed an internal medicine residency at Case-Western Reserve University and a fellowship in medical oncology at the NCI. He is board certified in internal medicine and medical oncology.

Eliav Barr, MD

Dr. Eliav Barr became head of Global Clinical Development (GCD) and Chief Medical Officer, Merck Research Laboratories (MRL), in April 2022. Previously he was Senior Vice President, Global Clinical Development and he has held positions of increasing responsibility including leadership roles in oncology and infectious diseases clinical development. Barr oversaw the company’s Vaccines/Infectious Disease area during a period of high productivity, including the development of novel therapies for chronic hepatitis C and HIV-1 infections. Most recently he led MRL’s Global Medical Affairs organization from 2018 to January 2022, significantly expanding Merck’s scientific engagement and implementation efforts in oncology, vaccines and more. In his latest role Barr leads all late-stage clinical development for Merck’s expansive human health portfolio and pipeline. Barr led the development of Merck’s human papillomavirus (HPV) vaccines, which have become key tools in the global effort to reduce the burden of certain cancers and diseases caused by HPV. Barr is a cardiologist by training. He received his undergraduate degree from Penn State University and his medical degree from Sidney Kimmel Medical College, Thomas Jefferson University. He completed his Internal Medicine residency and Cardiology Fellowship at Johns Hopkins University, and subsequently pursued post-doctoral training at the University of Michigan. Prior to joining Merck in 1995, he held a faculty position at the University of Chicago. In 2019, he received a Penn State Alumni Fellow Award for his dedication to the development of medicines and vaccines that treat and prevent infectious diseases.

Craig L. Tendler, MD​

Craig Tendler, M.D. is Vice President and Global Head of Clinical Development, Diagnostics, and Medical Affairs for the Oncology Therapeutic Area at Janssen Research & Development, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. In this position, he is responsible for creating and overseeing robust development plans, including optimal integration of biomarkers and diagnostics, and comprehensive data generation activities for all products in the oncology portfolio, from proof of concept through registration and lifecycle management. He works closely with teams in early development and the disease areas of focus to implement a seamless end-to-end oncology clinical research strategy that incorporates compelling science, broad clinical trial access to diverse populations, and addresses areas of high unmet medical need. Prior to this role, Craig served as Vice President of Medical Affairs for Tibotec Therapeutics and then Ortho-Biotech, where he led medical affairs teams in lifecycle management and data generation for the Janssen Virology and Oncology franchises. Craig has overseen and coordinated more than 30 major drug approvals by national regulatory agencies, including at least ten NDAs by the US Food and Drug Administration (FDA). He and his have team worked in collaboration with the FDA and the European Medicines Agency to secure the worldwide approvals of Janssen’s treatments in prostate cancer, hematologic malignancies, as well as for lung and bladder cancer. Further, together with his team, Craig has been instrumental in achieving 11 FDA breakthrough designations for accelerating the early development of promising investigational medicines intended for the treatment of serious oncology conditions. Prior to joining Janssen, Craig served as the Vice President of Oncology Clinical Research and Chair of the Oncology Licensing Committee at the Schering-Plough Research Institute. In addition to his pharmaceutical industry experience, he has served as Assistant Professor of Pediatrics/Hematology-Oncology at the Mount Sinai School of Medicine in New York City and as a research fellow at the National Cancer Institute in Bethesda, Maryland. Craig earned his undergraduate degree from Cornell University, and graduated from the Mount Sinai School of Medicine, New York City, with high honors and induction into the Alpha Omega Alpha Medical Society.

Tara Frenkl, MD, MPH​

Tara is senior vice president and head of Global Medical Strategy and Integrated Evidence Generation at Bayer Pharmaceuticals. As Head of Oncology Development at Bayer, she is responsible for late clinical development strategy, clinical operations, data analytics project management and regulatory affairs shaping the oncology portfolio as well as fostering the cross functional collaboration that is crucial to transforming science into therapies and medicines.

Tara earned her MD, MPH and B.S in Pharmacy from Rutgers University. She went on to complete residency at Brown University and fellowship at the Cleveland Clinic. Tara’s pharmaceutical career began at Merck where she worked across multiple therapeutic areas, including leading the development and approval of pembrolizumab for several different stages of bladder cancer. More recently at GSK, she held the role of Senior Vice President, Head of Medicine Development Leaders in Oncology at GlaxoSmithKline, with strategic impact on the global development across the company’s Oncology portfolio, and how best to deliver differentiated medicines to cancer patients.

​Peter Sandor, MD, MBA

Dr. Peter Sandor has 25 years of biopharmaceutical leadership experience and currently serves as the senior vice president, Primary Focus Lead, Primary Focus Immuno-oncology at Astellas. In his role, Dr. Sandor has responsibility for leading the strategic direction of Astellas’ early immuno-oncology research and development pipeline and plays an integral role in the expansion of Astellas’ presence in oncology. Dr. Sandor has previously served as vice president, Head of Marketing Strategy, Oncology at Astellas. Prior to Astellas, he was Head of Global Marketing Oncology at Amgen, held several global leadership positions at Bayer Healthcare, led the global launch of a key oncology compound for Berlex and held multiple marketing roles with Schering AG in Germany and Hungary, respectively. Dr. Sandor began his career in academia as a scientific advisor to the Hungarian Academy of Sciences. He earned his Doctor of Medicine at the University of Pécs, Hungary, his Master of Business Administration from Middlesex University, London and Faculty of Business and Economy, University of Pécs, Hungary, and his Postgraduate Degree in Marketing from the University of Pécs, Hungary.

​Stuart “Stu” Bailey, DPhil

​​Jean-Charles Soria, MD, PhD

Jean-Charles Soria is Amgen’s Senior Vice President of Oncology within Global Development. Soria joined Amgen from Institut Gustave Roussy, where he was appointed director general by France’s Minister of Health and Solidarity. Soria is a medical oncologist and professor of medicine at Paris-Saclay University. He holds a doctorate in molecular biology. He completed his training during a two-year appointment at the MD Anderson Cancer Center in Houston, Texas, U.S., where he was an associate professor from 2013 to 2017. He also served as the director of the Gustave Roussy SIRIC Socrate (Integrated Cancer Research Site) from 2012 to 2017.From 2017 to 2019 he held the role of senior vice president, Research and Development in Oncology, with AstraZeneca in Gaithersburg, Maryland, U.S., where he led research teams responsible for strategy and for development of new agents in immuno-oncology, cell therapy and conjugated antibodies. Additionally, he has authored or co-authored more than 670 articles in leading international journals and has appeared on lists of the most influential research scientists in the world.

​Brian Alexander, MD

Brian Alexander, MD, is SVP at Roche/Genentech Phrama R7D. He was previosuly Chief Executive Officer of Foundation Medicine in March 2021. Prior to that, he served as the company’s Chief Medical Officer, and practiced radiation oncology specializing in neuro-oncology at Dana-Farber Brigham Cancer Center. He is also a Senior Lecturer at Harvard Medical School. Dr. Alexander joined Foundation Medicine in September 2018 as a Senior Vice President of Clinical Development, and has since played a pivotal leadership role in Foundation Medicine’s decision insights strategy, helping oncologists, both in community and academic settings, determine the right treatment, at the right time, for each unique patient. Under his leadership, Foundation Medicine secured FDA approval of its liquid biopsy test, FoundationOne Liquid® CDx, issued its one millionth patient report and launched the company’s personalized circulating tumor DNA (ctDNA) monitoring assay, FoundationOne® Tracker.He was the founding director of the Program in Regulatory Science at the Dana-Farber Cancer Institute and the Harvard/MIT Center for Regulatory Science. He also co-founded the Global Coalition for Adaptive Research, a non-profit organization focused on clinical trial innovations to accelerate the discovery and development of cures for patients with rare and deadly diseases, and served as chair of the FDA/Project Datasphere task force on external control arms. Dr. Alexander is an affiliated researcher at the MIT Laboratory for Financial Engineering and affiliated faculty of the Harvard Kennedy School Healthcare Policy Program. He was named to Boston Magazine’s “Top Doctors List” in 2019, 2020, 2021, 2022 and 2023.Previously, Dr. Alexander served as a White House fellow and Special Assistant to the Secretary of Veterans Affairs (VA), where he helped prepare the VA for the transition of administrations, worked to develop a public reporting system for quality, and served as a health policy advisor to the Secretary. Dr. Alexander organized the standup of the VA’s Coordinating Council on National Health Reform and directed the activities of its multi-team Health Reform Working Group. He was also a member of the Institute of Medicine’s Committee on the Governance and Financing of Graduate Medical Education. Dr. Alexander’s research interests focus on innovations in clinical evidence generation to support the development of therapeutics, biomarkers, and novel endpoints. He co-authored a book titled “Diagnostic Test Interpretation and Reasoning Under Uncertainty,” detailing the use of Bayesian approaches to clinical decision-making. Dr. Alexander was the founding principal investigator of INSIGhT, a multi-institutional genomic biomarker-based Bayesian adaptively randomized trial for patients with glioblastoma. He is the recipient of the Burroughs-Wellcome Innovations in Regulatory Science Award for his work applying such approaches to clinical trial design. Dr. Alexander received his B.A. from Kalamazoo College, M.D. from the University of Michigan Medical School, and M.P.H. from the Harvard School of Public Health. He completed his training in radiation oncology at the Harvard Radiation Oncology Program.

Emily Morris-McCarthy

Emily Morris-McCarthy is the general manager, head U.S. oncology for Sanofi. She previously served as franchise head for alliance/immuno-oncology and senior director of marketing for U.S. immuno-oncology marketing at Sanofi. Before coming to Sanofi, she was senior director of U.S. oncology marketing for EMD Serono. She earned a master of arts degree from La Salle University and a bachelor of arts degree from the Massachusetts College of Liberal Arts.

William C. Weldon

William C. Weldon is Chairman of the Board of Johnson & Johnson. He assumed his current responsibilities in April, 2002. Previously Bill served as Worldwide Chairman, Pharmaceuticals Group, and a Vice Chairman of the Board of Directors. He was elected to the Board in February 2001.Bill joined Johnson & Johnson in 1971 in the sales and marketing department of its McNeil Pharmaceutical subsidiary. In 1982 he was named manager, ICOM Regional Development Center in Southeast Asia. Bill was appointed executive vice president and managing director of Korea McNeil, Ltd., in 1984 and managing director of Ortho-Cilag Pharmaceutical, Ltd., in the U.K. in 1986. In 1989, he was named vice president of sales and marketing at Janssen Pharmaceutica in the U.S., and in 1992 he was appointed president of Ethicon Endo-Surgery. In 1995, Bill was named a company group chairman of Johnson & Johnson and Worldwide Franchise Chairman of Ethicon Endo-Surgery, the Johnson & Johnson affiliate that develops new procedures for minimally-invasive surgery and designs related products. In 1998, Bill was promoted to the Executive Committee and named Worldwide Chairman, Pharmaceuticals Group. Among his outside activities, Bill is a member of the Board of Directors of JPMorgan Chase & Co and the US – China Business Council. He is also the immediate past Chairman of the CEO Roundtable on Cancer, a member of The Business Council, and a member of the Healthcare Leadership Council. Bill also serves as a member of the Board of Trustees for Quinnipiac University. He previously served as Chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA). Bill was born in Brooklyn, NY, and is a graduate of Quinnipiac University in Hamden, Connecticut. He and his wife have two children. Caring for the world, one person at a time

Martin J. Murphy, DMedSc, PhD, FASCO

Dr. Martin J. Murphy in 1999 accepted the challenge from President George H. W. Bush to help create and lead what would become the CEO Roundtable on Cancer as its Founding Chief Executive Officer, a role he which he served for the next two decades. He became Emeritus Director of the CEO Roundtable on Cancer’s Board of Directors in 2020. He is Founding CEO of Shanghai TuoXin Health Promotion Center, the CEO Roundtable’s independent China counterpart.Dr. Murphy was also Founding CEO of Project Data Sphere, LLC, a non-profit enterprise devoted to cancer clinical trial data-transparency, data-sharing and data-analysis originally developed by the CEO Roundtable on Cancer. He retired from its Board of Directors in 2020.Dr. Murphy is a member of the National Cancer Policy Forum of the National Academy of Medicine of the U.S. National Academy of Sciences; director emeritus of the Foundation for the National Institutes of Health (FNIH). He is a Fellow of the American Society of Clinical Oncology (ASCO), Co-Chairman of the Strategic & Scientific Advisory Council of the COVID-19 International Data Alliance (ICODA), member of the Global Health Forum, Boao Forum for Asia, and founding editor of three international peer-reviewed biomedical journals: The Oncologist, Stem Cells and Stem Cells Translational Medicine.Co-founder of the Society for Translational Oncology; a member of the Scientific Advisory Board of Hatteras Venture Partners; a charter member of the International Advisory Board of the VU University Medical Imaging Center (Amsterdam); a charter member of Queen’s University Belfast School of Medicine International Review Board, Dr. Murphy is also chairman emeritus of Conquer Cancer, the ASCO Foundation; convener of ACT-China; and Steering Committee member of the Chinese Society of Clinical Oncology (CSCO). He is Senior Oncology Consultant to China’s National Medical Products Administration (NMPA). In November 2021 he was an invited delegate to the Bloomberg New Economy Forum (Singapore) that launched the International Cancer Coalition. He is a director of the Sino-American biotech, Brii Biosciences, Inc. (Hong Kong Stock Exchange, 2137), and a director of Helsinn-China, Ltd. Dr. Murphy is the 2022 recipient of the Ellis Island Medal of Honor bestowed on those who have, “shown the best of America by outstanding commitment to serving our nation professionally, culturally and civically.”

​Robert A. Bradway

Robert A. Bradway is Amgen’s chairman and chief executive officer. Bradway became chairman in January 2013 and chief executive officer in May 2012. Bradway served as the company’s president and chief operating officer from May 2010 to May 2012, and was appointed to the Amgen Board of Directors in October 2011. He joined the company in 2006 as vice president, Operations Strategy, and served as executive vice president and chief financial officer from April 2007 to May 2010.Prior to joining Amgen, he was a managing director at Morgan Stanley in London where, beginning in 2001, he had responsibility for the firm’s banking department and corporate finance activities in Europe. Bradway joined Morgan Stanley in New York as a health care industry investment banker in 1985 and moved to London in 1990.He served as the chairman of the CEO Roundtable on Cancer from 2015 up until 2022. Amgen has been a member of the CEO Roundtable on Cancer since 2014, the same year the company earned Gold Standard Accreditation in the US. Amgen earned Gold Standard accreditation in China in 2017. The company also has been a data contributor to Project Data Sphere since 2015.He is a member of the board of directors of The Boeing Company, serving on its Audit and Finance committees. Bradway serves on the board of trustees of the University of Southern California and on the advisory board of the Leonard D. Schaeffer Center for Health Policy and Economics at that university. He is a member of the American Heart Association CEO Roundtable on Cancer, which is helping the Association meet its goal of improving the cardiovascular health of all Americans. He is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA) board of directors. He also sits on the board of directors for both Boeing and the Norfolk Southern Railway Corporation. Bradway holds a bachelor’s degree in biology from Amherst College and a master’s degree in business administration from Harvard University.

Peter Guenter​

Peter Guenter is a member of the Executive Board of Merck and CEO of Healthcare. He joined Merck in January 2021.Before joining Merck, Guenter served as CEO of Spanish pharma company Almirall from 2017 to 2020. Prior to that, he spent 22 years at Sanofi, serving as a member of the Executive Committee since 2013. In his most recent role at Sanofi, he served as executive vice president of the company’s Global Diabetes and Cardiovascular unit. Previous roles with Sanofi included responsibility for Global Commercial Operations, Emerging Markets, as well as various marketing, regional and country management roles. Guenter holds a master’s degree in physical education from the Faculty of Medicine and Health Sciences of the University of Ghent.

Scott White​

Scott White is Company Group Chairman, North America, at the Janssen Pharmaceutical Companies of Johnson & Johnson. A member of the Pharmaceuticals Group Operating Committee, he is responsible for leading Janssen’s efforts to transform the health of people in the U.S. and Canada facing cancer, autoimmune disease, heart disease and diabetes, infectious diseases including HIV, pulmonary arterial hypertension, and serious mental illness. In his 30-year career at Janssen, White has led some of the company’s most significant businesses across multiple serious disease areas. He is a results-focused leader, widely respected for his strategic insight and commitment to developing high-performing, diverse teams. As President, Janssen U.S. Immunology, White led Johnson & Johnson’s largest business, making a significant difference for people with debilitating autoimmune diseases through highly impactful medicines and innovative patient support and access programs. Prior to his Immunology role, he was President of Janssen U.S. Oncology. Under White’s leadership, Janssen launched two transformational cancer treatments making Janssen Oncology one of the fastest growing oncology businesses in the U.S. Previously, he held the position of Vice President, Strategic Customer Group, serving all Janssen U.S. businesses, where he led contracting and account management. In this critical role, he served as the market access leader to ensure people who need our medicines have access to them. White represents Johnson & Johnson on the Board of Directors of the Biotechnology Innovation Organization (BIO), the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations. He holds a Bachelor of Arts from Rutgers, The State University of New Jersey, where he double-majored in molecular biology and philosophy. He also received a Master of Business Administration from the University of Phoenix.